我们进行了一项临床试验旨在分析伏立康唑在急性髓细胞白血病化疗诱导阶段预防肺部浸润的有效性和安全性。
We conducted a trial to analyze the efficacy and safety of voriconazole in the prevention of lung infiltrates during induction chemotherapy for acute myelogenous leukaemia (AML).
在急性髓细胞性白血病aml和急性淋巴细胞性白血病all中，原始的急性白血病细胞进展、形成多达上亿个的白血病细胞。
In acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL), the original acute leukemia cell goes on to form about a trillion more leukemia cells.
在第一方面的实施方案中，所述急性髓性白血病是复发性急性髓性白血病。
In an embodiment of the first aspect, the acute myelogenous leukemia is relapsed acute myelogenous leukemia.
MA9常见于急性髓性白血病，偶尔也在急性淋巴白血病中发现，并且会导致较差的预后。
MA9 is commonly found in acute myeloid leukemia (AML) and occasionally in acute lymphoid leukemia and is associated with intermediate to poor outcome.
MA9常见于急性髓性白血病，偶尔也在急性淋巴白血病中发现，并且会导致较差的预后。
MA9 is commonly found in acute myeloid leukemia (AML) and occasionally in acute lymphoid leukemia and is associated with intermediate to poor outcome.
应用推荐